

## DAFTAR PUSTAKA

1. World Health Organization. Diabetes [Internet]. Fact Sheets. 2021 [cited 2022 Mar 31]. Available from: <https://www.who.int/news-room/fact-sheets/detail/diabetes>
2. Sapra A, Bhandari P. Diabetes Mellitus. StatPearls. 2021 Sep 18 [cited 2022 Mar 27]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK551501/>
3. Cho N, Kirigia J, Ogurstova K, Reja A. IDF Diabetes Atlas 10th Edition [Internet]. 10th Edtio. Boyko JE, Magliano JD, Karuranga S, Piemonte L, Riley P, Saeedi P, et al., editors. International Diabetes Federation; 2021. 1–150 p. Available from: [www.diabetesatlas.org](http://www.diabetesatlas.org)
4. Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan. Laporan Provinsi Sumatera Barat Riskesdas 2018. Tim Riskesdas 2018, editor. Laporan Riskesdas Nasional 2018. Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan; 2018. 493 p.
5. Igly K, Hannachi H, Howie PJ, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. <https://doi.org/10.1185/0300799520161168291>. 2016 Jul 2 [cited 2022 Mar 30];32(7):1243–52. Available from: <https://www.tandfonline.com/doi/abs/10.1185/03007995.2016.1168291>
6. Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. *J Clin Hypertens (Greenwich)*. 2011 Apr [cited 2022 Mar 30];13(4):244–51. Available from: <https://pubmed.ncbi.nlm.nih.gov/21466619/>
7. Kementerian Kesehatan RI. InfoDatin Hipertensi. 2014;1–6.
8. Iqbal AM, Jamal SF. Essential Hypertension. *xPharm Compr Pharmacol Ref*. 2022 Feb 14 [cited 2022 Mar 31];1–6. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539859/>
9. World Health Organization. Hypertension [Internet]. Fact Sheets. 2021 [cited 2022 Apr 2]. Available from: <https://www.who.int/news-room/fact-sheets/detail/hypertension>
10. Diana EDN, Nugraha W, Rahma A, Oktafiani FA, Widyaswari R, Irawanto ME. Profil Pemphigus Vulgaris Di Instalasi Rawat Inap RSUD Dr . Moewardi Surakarta Periode Januari 2014-Desember 2019. *Medicinus*. 2021;34(3):27–34.
11. Hsu DY, Brieva J, Nardone B, West D, Silverberg JI. Association of pemphigus and systemic corticosteroid use with comorbid health disorders: A case-control study. *Dermatol Online J*. 2017 [cited 2022 Jan 12];23(12):1–

1. Available from: <https://escholarship.org/uc/item/1vk2m30m>
12. Tamgadge S, Bhatt D, Pereira T, Tamgadge A, Bhalerao S. Pemphigus vulgaris. *Contemp Clin Dent*. 2011 [cited 2021 Jun 28];2(2):134. Available from: <http://www.contempclindent.org/text.asp?2011/2/2/134/83074>
13. Benny E. Wiryadi. Dermatosis vesikobulosa kronik. In: Menaldi SL, Bramono K, Indriatmi W, editors. *Ilmu Penyakit Kulit dan Kelamin*. 7th ed. Jakarta: Badan Penerbitan FKUI; 2016. p. 234–8. Available from: <http://www.bpfkui.com/>
14. Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. *J Cell Mol Med*. 2007 May [cited 2021 Nov 5];11(3):462. Available from: </pmc/articles/PMC3922353/>
15. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. *J Clin Invest*. 2006 May 1 [cited 2021 Nov 5];116(5):1159. Available from: </pmc/articles/PMC1451217/>
16. Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, et al. Pemphigus. *Nat Rev Dis Prim*. 2017 May 11 [cited 2021 Nov 20];3:17026. Available from: </pmc/articles/PMC5901732/>
17. Sofwan NY, Suryawati N, Khatreen C, Pangaribuan O. Profil Penyakit Bula Autoimun di Klinik Rawat Jalan Dermatologi dan Venereologi RSUP Sanglah Denpasar Periode April 2016–Desember 2017. *Media Dermato-Venereologica Indones*. 2020;47(April 2020):112–7.
18. Kridin K, Zelber-Sagi S, Khamaisi M, Cohen AD, Bergman R. Remarkable differences in the epidemiology of pemphigus among two ethnic populations in the same geographic region. *J Am Acad Dermatol*. 2016 Nov 1 [cited 2021 Jun 30];75(5):925–30. Available from: <https://pubmed.ncbi.nlm.nih.gov/27614531/>
19. Meyer N, Misery L. Geoepidemiologic considerations of auto-immune pemphigus. *Autoimmun Rev*. 2010;9(5):A379–82. Available from: <http://dx.doi.org/10.1016/j.autrev.2009.10.009>
20. Porro AM, Seque CA, Ferreira MCC, E Silva Enokihara MMS. Pemphigus vulgaris. *An Bras Dermatol*. 2019 May 1 [cited 2021 Jul 1];94(3):264–78. Available from: </pmc/articles/PMC6668932/>
21. Asilian A, Yoosefi A, Faghini G. Pemphigus vulgaris in Iran: epidemiology and clinical profile. *Skinmed*. 2006 [cited 2021 Dec 1];5(2):69–71. Available from: <https://pubmed.ncbi.nlm.nih.gov/16603836/>
22. Wardhana M, Rusyati LM. Prevalence And Quality Of Life Of Pemphigus Patients At Sanglah General Hospital Bali-Indonesia. *Bali Med J*. 2013;2(1):42–5.
23. Surya N. Karakteristik Pasien Pemfigus Vulgaris Di Rsup H. Adam Malik

Medan Periode Tahun 2009-2013. 2014;

24. Ghodsi SZ, Chams-Davatchi C, Daneshpazhooh M, Valikhani M, Esmaili N. Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaires. *J Dermatol*. 2012 [cited 2021 Dec 4];39(2):141–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/21967321/>
25. Joly P, Horvath B, Patsatsi, Uzun S, Bech R, Beissert S, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). *J Eur Acad Dermatology Venereol*. 2020 Sep 1 [cited 2021 Nov 7];34(9):1900–13. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.16752>
26. Cholera M, Chainani-Wu N. Management of Pemphigus Vulgaris. *Adv Ther*. 2016 Jun 1 [cited 2021 Nov 30];33(6):910. Available from: </pmc/articles/PMC4920839/>
27. Darjani A, Nickhah N, Emami MHH, Alizadeh N, Rafiei R, Eftekhari H, et al. Assessment of the Prevalence and Risk Factors Associated With Glucocorticoid-Induced Diabetes Mellitus in Pemphigus Vulgaris Patients. *Acta Med Iran*. 2017 Aug 19 [cited 2022 Jan 13];78(11):375–80. Available from: <https://acta.tums.ac.ir/index.php/acta/article/view/5561>
28. Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. *Diabetes Metab Res Rev*. 2014 Feb [cited 2022 Jan 13];30(2):96. Available from: </pmc/articles/PMC4112077/>
29. Mebrahtu TF, Morgan AW, West RM, Stewart PM, Pujades-Rodriguez M. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: A population-based cohort study. *CMAJ*. 2020 Mar 23 [cited 2022 Jan 17];192(12):E295–301. Available from: <https://www.cmaj.ca/content/192/12/E295>
30. Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. *Clin Ther*. 2017 Nov 1 [cited 2022 Jan 17];39(11):2216–29. Available from: <https://pubmed.ncbi.nlm.nih.gov/29055500/>
31. Heelan K, Mahar AL, Walsh S, Shear NH. Pemphigus and associated comorbidities: a cross-sectional study. *Clin Exp Dermatol*. 2015 Aug 1 [cited 2022 Jan 15];40(6):593–9. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/ced.12634>
32. Ruocco V, Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. *Int J Dermatol*. 1991 [cited 2021 Oct 22];30(5):307–12. Available from: <https://pubmed.ncbi.nlm.nih.gov/1829722/>
33. Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, Dmochowski M. A retrospective study of antihypertensives in pemphigus: a

still uncharted odyssey particularly between thiols, amides and phenols. Arch Med Sci. 2015 [cited 2022 Apr 4];11(5):1021. Available from: /pmc/articles/PMC4624747/

34. Jameson L, Lindsay R, Cosman F. Harrison's Endocrinology. 4th Editio. Hauser S, Dennis K, editors. McGraw- Hill. Philadelphia,: Mc Graw Hill; 2017. 480–502 p.
35. Gardner DG, Shoback D. Greenspan' s basic & clinical endocrinology. 9th editio. McGrawHill Medical. San Francisco: McGrawHill; 2018. 595–680 p.
36. Badan Penelitian dan Perkembangan Kesehatan Kementrian Kesehatan Republik Indonesia. Laporan Nasional Riskesdas 2018 [Internet]. Badan Penelitian dan Pengembangan Kesehatan. Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan; 2018. Available from: [http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan\\_Nasional\\_RKD2018\\_FINAL.pdf](http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf)
37. Speight J, Pouwer F. Diabetes Mellitus Type 1. Cambridge Handb Psychol Heal Med Third Ed. 2021 Jul 26 [cited 2022 Apr 11];477–80. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK507713/>
38. Goyal R, Jialal I. Diabetes Mellitus Type 2. Verdure Heal Sci J. 2021 Sep 28 [cited 2022 Apr 11];3(1):8–17. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK513253/>
39. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun 1 [cited 2022 Apr 21];75(6):1334–57. Available from: <https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.120.15026>
40. Alexander MR, Madhur MS, Harrison DG. Hypertension [Internet]. Medscape Practice Essentials. 2019 [cited 2022 Apr 26]. Available from: <https://emedicine.medscape.com/article/241381-overview>
41. Bakris GL. Hypertension [Internet]. MSD Manual Professional Edition. 2021 [cited 2022 Apr 26]. Available from: <https://www.msmanuals.com/professional/cardiovascular-disorders/hypertension/hypertension>
42. Carretero OA, Oparil S. Essential Hypertension. Circulation. 2000 Jan 25 [cited 2022 Apr 26];101(3):329–35. Available from: <https://www.ahajournals.org/doi/abs/10.1161/01.CIR.101.3.329>
43. Perhimpunan Dokter Hipertensi Indonesia. Konsensus Penatalaksanaan Hipertensi 2021 : Update Konsensus PERHI 2019. Lukito AA, Harmeiwaty E, Situmorang TD, Hustrini NM, Kuncoro AS, Barack R, et al., editors. Jakarta: Perhimpunan Dokter Hipertensi Indonesia; 2021. 25–36 p.

44. Kementerian Kesehatan Republik Indonesia. Panduan praktik klinis bagi dokter pelayanan primer. Edisi 1. Kemenkes RI. Jakarta: Kementerian Kesehatan RI; 2017.
45. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* (London, England). 2002 Dec 14 [cited 2022 Apr 30];360(9349):1903–13. Available from: <https://pubmed.ncbi.nlm.nih.gov/12493255/>
46. Burgan SZ, Sawair FA, Napier SS. Case report: Oral pemphigus vulgaris with multiple oral polyps in a young patient. *Int Dent J*. 2003 Feb 1 [cited 2021 Jun 27];53(1):37–40. Available from: <https://pubmed.ncbi.nlm.nih.gov/12653338/>
47. Kridin K, Schmidt E. Epidemiology of Pemphigus. *JID Innov*. 2021 Mar 1;1(1):100004.
48. Hietanen J, Salo OP. Pemphigus: An epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. *Acta Derm Venereol*. 1982;62(6):491–6.
49. Simon DG, Krutchkoff D, Kaslow RA, Zarbo R. Pemphigus in Hartford County, Connecticut, From 1972 to 1977. *Arch Dermatol*. 1980 Sep 1 [cited 2021 Nov 27];116(9):1035–7. Available from: <https://jamanetwork.com/journals/jamadermatology/fullarticle/541358>
50. Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Esmaili N, Balighi K, Hallaji Z, et al. Pemphigus: Analysis of 1209 cases. *Int J Dermatol*. 2005 Jun 1 [cited 2021 Nov 27];44(6):470–6. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-4632.2004.02501.x>
51. Pisanti S, Sharav Y, Kaufman E, Posner LN. Pemphigus vulgaris: Incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. *Oral Surgery, Oral Med Oral Pathol*. 1974 Sep 1;38(3):382–7.
52. Stanley JR. Pemphigus. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel DJ, editors. *Fitzpatrick's Dermatology in General Medicine*. Seventh. New York: Mc Graw Hill; 2008. p. 459–68.
53. Hübner F, König IR, Holtsche MM, Zillikens D, Linder R, Schmidt E. Prevalence and age distribution of pemphigus and pemphigoid diseases among paediatric patients in Germany. *J Eur Acad Dermatology Venereol*. 2020 Nov 1 [cited 2021 Nov 27];34(11):2600–5. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.16467>
54. Nanda A, Dvorak R, Al-Saeed K, Al-Sabah H, Alsaleh QA. Spectrum of autoimmune bullous diseases in Kuwait. *Int J Dermatol*. 2004 Dec 1 [cited 2021 Nov 27];43(12):876–81. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-4632.2004.02292.x>

55. Tsankov N, Vassileva S, Kamarashev J, Kazandjieva J, Kuzeva V. Epidemiology of pemphigus in Sofia, Bulgaria. A 16-year retrospective study (1980-1995). *Int J Dermatol*. 2000;39(2):104–8.
56. Adam BA. Bullous Diseases In Malaysia: Epidemiology And Natural History. *Int J Dermatol*. 1992 Jan 1 [cited 2021 Nov 27];31(1):42–5. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-4362.1992.tb03519.x>
57. Grau-Pérez M, Gómez-Duaso AJ, Sánchez-García F, de la Rosa-del Rey P, González-Martín JM, Carretero-Hernández G. Epidemiological and genetic data suggest the presence of an endemic form of pemphigus foliaceus in Gran Canaria, Spain. *Br J Dermatol*. 2019 Apr 1 [cited 2021 Nov 27];180(4):945–6. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.17346>
58. Ingold CJ, Khan MA. Pemphigus Vulgaris. 2021 May 1 [cited 2021 Jul 1]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK560860/>
59. Lombardi M, Mercurio O, Ruocco V, Lo Schiavo A, Lombardi V, Guerrera V, et al. Common human leukocyte antigen alleles in pemphigus vulgaris and pemphigus foliaceus Italian patients. *J Invest Dermatol*. 1999 [cited 2021 Oct 22];113(1):107–10. Available from: <https://pubmed.ncbi.nlm.nih.gov/10417627/>
60. Vodo D, Sarig O, Sprecher E. The Genetics of Pemphigus Vulgaris. *Front Med*. 2018 [cited 2021 Nov 5];5(AUG):226. Available from: </pmc/articles/PMC6102399/>
61. Parameswaran A, Attwood K, Sato R, Seiffert-Sinha K, Sinha AA. Identification of a new disease cluster of pemphigus vulgaris with autoimmune thyroid disease, rheumatoid arthritis and type I diabetes. *Br J Dermatol*. 2015 Mar 1 [cited 2021 Nov 29];172(3):729–38. Available from: <https://pubmed.ncbi.nlm.nih.gov/25272088/>
62. Robbins A, Lazarova Z, Janson M, Fairley J. Pemphigus vulgaris presenting in a radiation portal. *J Am Acad Dermatol*. 2007 May [cited 2021 Oct 23];56(5 Suppl). Available from: <https://pubmed.ncbi.nlm.nih.gov/17434046/>
63. Ruocco V, Ruocco E, Lo Schiavo A, Brunetti G, Guerrera L, Wolf R. Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies. *Clin Dermatol*. 2013 Jul [cited 2021 Oct 22];31(4):374–81. Available from: <https://pubmed.ncbi.nlm.nih.gov/23806154/>
64. Vincenzo Ruocco, Satriano R, Guerrera V. “Two-step” pemphigus induction by ACE-inhibitors. *Int J Dermatol*. 1992 [cited 2021 Oct 22];31(1):33–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/1737686/>
65. Amagai M, Kazuyuki T, D Z, T N, T N. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. *J Am Acad Dermatol*.

- 1999 [cited 2021 Nov 5];40(2 Pt 1):167–70. Available from: <https://pubmed.ncbi.nlm.nih.gov/10025740/>
66. Didona D, Maglie R, Eming R, Hertl M. Pemphigus: Current and future therapeutic strategies. *Front Immunol*. 2019 Jun 1;10:1418.
  67. Dagistan S, Goregen M, Miloglu O, Cakur B. Oral pemphigus vulgaris: a case report with review of the literature. *J Oral Sci*. 2008 [cited 2021 Nov 30];50(3):359–62. Available from: <https://pubmed.ncbi.nlm.nih.gov/18818476/>
  68. Kavala M, Topaloğlu Demir F, Zindanci I, Can B, Turkoğlu Z, Zemheri E, et al. Genital involvement in pemphigus vulgaris (PV): correlation with clinical and cervicovaginal Pap smear findings. *J Am Acad Dermatol*. 2015 Oct 1 [cited 2021 Nov 5];73(4):655–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/26194705/>
  69. Kumar S, Nehru Anand S, Gunasekaran N, Krishnan R. Oral pemphigus vulgaris: A case report with direct immunofluorescence study. *J Oral Maxillofac Pathol*. 2016 Sep 1 [cited 2021 Nov 9];20(3):549. Available from: <https://pubmed.ncbi.nlm.nih.gov/3051317/>
  70. Tsuruta DGbr, Hashimoto T. IgA Pemphigus. *Blistering Dis Clin Featur Pathog Treat*. 2021 Jul 23 [cited 2021 Nov 9];299–305. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK519063/>
  71. Mirza HA, Gharbi A, Bhutta BS. Dermatitis Herpetiformis. *StatPearls*. 2021 Aug 7 [cited 2021 Nov 9]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK493163/>
  72. Baigrie D, Nookala V. Bullous Pemphigoid. *StatPearls*. 2020 Dec 9 [cited 2021 Nov 9]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK535374/>
  73. Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia. *Panduan Praktik Klinis Bagi Dokter Spesialis Kulit dan Kelamin*. Widaty S, Soebono H, Nilasari H, Listiawan Y, Siswati AS, Triwahyudi D, et al., editors. Jakarta: PERDOSKI; 2017. 221–224 p.
  74. Bystryrn J-C, Steinman NM. The Adjuvant Therapy of Pemphigus: An Update. *Arch Dermatol*. 1996 Feb 1 [cited 2021 Nov 28];132(2):203–12. Available from: <https://jamanetwork.com/journals/jamadermatology/fullarticle/557517>
  75. Kridin K, Zelber-Sagi S, Bergman R. Mortality and cause of death in patients with pemphigus. *Acta Derm Venereol*. 2017;97(5):607–11.
  76. Suh S, Park MK. Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem. *Endocrinol Metab*. 2017 Jun 1 [cited 2022 Jan 17];32(2):180. Available from: <https://pubmed.ncbi.nlm.nih.gov/28503862/>

77. Valikhani M, Khoshniat Niko M, Naser Tork A. Risk Factors And Frequency Of Steroid - Induced Diabetes In Pemphigus Vulgaris Patients During 1 Year Study. *Iran J Diabetes Metab.* 2007 [cited 2022 Jan 16];6(3):301–7. Available from: <http://ijdl.tums.ac.ir/article-1-322-en.html>
78. Dănescu AS, Bâldea I, Leucuța DC, Lupan I, Samașca G, Sitaru C, et al. Immunological markers as predictors of developing steroid-induced diabetes mellitus in pemphigus vulgaris patients: An observational study. *Medicine (Baltimore).* 2018 Apr 1 [cited 2022 Jan 17];97(17). Available from: </pmc/articles/PMC5944517/>
79. National Institute for Health and Care Excellence. Hypertension in adults: Diagnosis and management. 2019th ed. Vol. 49. NICE; 2019.
80. Masturoh I, Anggita N. Metodologi penelitian kesehatan. Vol. 1, Bahan Ajar Rekam Medis dan Informasi Kesehatan. Jakarta: Pusat Pendidikan Sumber Daya Manusia Kesehatan; 2018. 307 p.
81. Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. *Immunol Res.* 2018 Apr 1 [cited 2022 Jul 31];66(2):255–70. Available from: <https://pubmed.ncbi.nlm.nih.gov/29479654/>
82. Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. The Prevalence of Autoimmune Disorders in Women: A Narrative Review. *Cureus.* 2020 May 13 [cited 2022 Aug 13];12(5). Available from: </pmc/articles/PMC7292717/>
83. Goronzy JJ, Weyand CM. Immune aging and autoimmunity. *Cell Mol Life Sci.* 2012 May [cited 2022 Aug 14];69(10):1615. Available from: </pmc/articles/PMC4277694/>
84. Vadasz Z, Haj T, Kessel A, Toubi E. Age-related autoimmunity. *BMC Med.* 2013 Apr 4 [cited 2022 Aug 14];11(1):94. Available from: </pmc/articles/PMC3616810/>
85. Kementerian Pendidikan Kebudayaan Riset dan Teknologi Republik Indonesia. Ibu Rumah Tangga [Internet]. Kamus Besar Bahasa Indonesia. [cited 2022 Oct 3]. Available from: [https://kbbi.kemdikbud.go.id/entri/ibu\\_rumah\\_tangga](https://kbbi.kemdikbud.go.id/entri/ibu_rumah_tangga)
86. Patel F, Wilken R, Patel FB, Sultani H, Bustos I, Duong C, et al. Pathophysiology of Autoimmune Bullous Diseases: Nature Versus Nurture. *Indian J Dermatol.* 2017 May 1 [cited 2021 Oct 22];62(3):262. Available from: </pmc/articles/PMC5448260/>
87. Wohl Y, Brenner S. Pemphigus in Israel - An epidemiologic analysis of cases in search of risk factors. *Isr Med Assoc J.* 2003;5(6):410–2.
88. Fisher KR, Higginbotham R, Frey J, Granese J, Pillow J, Skinner RB. Pesticide-associated pemphigus vulgaris. *Cutis.* 2008;82(1):51–4.
89. Cura MJ, Torre AC, Cueto Sarmiento KY, Bollea Garlatti ML, Riganti J,



- Puga MC, et al. Pemphigus Vulgaris: A Retrospective Cohort Study of Clinical Features, Treatments, and Outcomes. *Actas Dermo-Sifiliográficas* (English Ed. 2020 Jun 1;111(5):398–407.
90. Esmaili N, Mortazavi H, Noormohammadpour P, Boreiri M, Soori T, Vasheghani Farahani I, et al. Pemphigus vulgaris and infections: A retrospective study on 155 patients. *Autoimmune Dis.* 2013;2013.
  91. Askin O. A Retrospective Analysis of Pemphigus Vulgaris Patients: Demographics, Diagnosis, Co-morbid Diseases and Treatment Modalities Used. *North Clin Istanbul.* 2020;
  92. Vasconcelos AC, Jr SAM, Figueiredo MA, Salum FG, Cherubini K. Pemphigus vulgaris: a review of 12 cases. *Rev Cubana Estomatol.* 2015 Sep 28 [cited 2021 Nov 30];52(3):29–33. Available from: <http://www.revestomatologia.sld.cu/index.php/est/article/view/514><http://www.revestomatologia.sld.cu/index.php/est/article/view/514>
  93. Anandan V, Jameela WA, Sowmiya R, Kumar MMS, Lavanya P. Rituximab: A Magic Bullet for Pemphigus. *J Clin Diagn Res.* 2017 Apr 1 [cited 2022 Aug 1];11(4):WC01. Available from: </pmc/articles/PMC5449891/>
  94. Chen DM, Oduyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. *Br J Dermatol.* 2020 May 1 [cited 2022 Aug 1];182(5):1111–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/31487383/>
  95. Ambiel MV, Roselino AM. Prevalence of metabolic syndrome and its components in a Brazilian sample of Pemphigus patients. *An Bras Dermatol.* 2014 [cited 2022 Apr 4];89(5):752–6. Available from: </pmc/articles/PMC4155953/>
  96. Phan K, Mangkorntongsakul V, Ramachandran V, Loya A, Smith SD. Pemphigus and diabetes mellitus: a systematic review and meta-analysis. *Int J Dermatol.* 2021 Jan 1 [cited 2022 Jan 13];60(1):e1–3. Available from: <https://pubmed.ncbi.nlm.nih.gov/33070309/>